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Interventional Cardiology,
Alive and Well at ACC.11 and i2 Summit 2011
There are many venues for reporting important research findings, and I am always interested
in how much will be unveiled at the Annual Scientific Sessions of the American College of
Cardiology (ACC). Because we had not inaugurated an interventional cardiologist as President
of the ACC since my tenure in 1998 to 1999, I was especially interested in how big a splash
intervention would make this year as we welcomed another interventional cardiologist, our own
Associate Editor, Dr. David R. Holmes, Jr., to take the helm of the College. I was not
disappointed. More than one-half of the late-breaking trials reported were on topics relevant to
interventions. The big hitter was obviously the PARTNER (Placement of Aortic
Transcatheter Valves) trial, a study of patients with high-risk aortic stenosis randomized to
percutaneous valve implantation or surgical placement. The results were encouraging for
further expansion of percutaneous valve implantation beyond the surgically inoperable group.
In addition, the economic analysis of the inoperable group B patients showed a projected
extension of life with the percutaneous valve of 1.9 years at a cost of $50,000 per life-year
gained—quite a positive result for a medical intervention. Dr. Martyn Thomas opined that
this might be attractive even to the “bean counters” in the United Kingdom. Among other
late-breakers that interested me was the PRECOMBAT (Bypass Surgery Versus Angioplasty
Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease) trial of
patients with left main disease, which adds significant weight to the SYNTAX (Synergy between
Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) left main subgroup findings.
This randomized trial provided strong evidence that selected left main patients can be managed
safely with stenting, and it will increase the discussion of what level of Class 2 indication (either A
or B) left main intervention should fall into. The other structural heart disease trial with clinical
impact was the 2-year follow-up of EVEREST-II (Endovascular Valve Edge-to-Edge Repair
Study). Although annual follow-up of trials without significant interval change is usually frowned
upon, that finding was what made this report so valuable. The 1-year results showing significantly
more mitral regurgitation with a mitral clip raised the question of whether clinical deterioration
would occur with further follow-up. The results were reassuring, as the degree of mitral
regurgitation did not change between years 1 and 2, and neither did the clinically-equivalent
outcomes. The RIVAL (Radial vs. Femoral Access for Coronary Intervention) trial, a comparison
of radial and femoral access for interventions, was somewhat sobering in this era of marked
enthusiasm for the radial approach in that it showed comparable results by either method, and the
difference was driven only by groin hematomas in the femoral group. Of the many double-
antiplatelet duration studies to come, the EXCELLENT trial, comparing 12- with 6-month
double-antiplatelet therapy, showed that overall there were no excess events with the shorter-
duration therapy, but a subgroup of diabetic patients did raise concerns for the abbreviated
treatment plan. The ISAR-CABG (Is Drug-Eluting Stenting Associated With Improved Results
in Coronary Artery Bypass Grafts) trial boosted drug-eluting stents (DES) for saphenous vein
grafts disease over bare-metal stents, but only for target vessel revascularization, without a difference in
hard endpoints. The delta was about 5 to 6 reinterventions per 100 cases avoided if DES were used.
Another one-half dozen late-breakers fell into the interventional camp. I took special
pleasure, however, in hearing Dr. Patrick Serruys report the 1-year follow-up of the ABSORB
(A Bioabsorbable Everolimus-Eluting Coronary Stent System) trial. This bioerodable stent
seems to be performing its stenting assignments well (i.e., scaffolding and reducing neointimal
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598proliferation) while beginning to actually resorb. The
presentation by Dr. Serruys was of particular interest to me
as I recalled conversations we had together more than 23
years ago about the dream of a stent that could do its job
and then go away, leaving a functional artery behind.
Despite our failures in the beginning (we worked on the
polymeric biodegradable stent idea in the late 1980s), this
development gave a new direction for vascular research. I
foresee many careers perfecting endovascular scaffolds and
solving the problems that may arise.
Thanks to all of the members of the editorial board
who participated in the joint JACC, JACC: Cardiovascular
Interventions, and JACC: Cardiovascular Imaging editorial
meeting, and also enjoyed a bit of levity. Dr. Jagat
Narula, Editor-in-Chief of JACC: Cardiovascular Imaging,
stole the show by unveiling his latest issue with the cover
showing the CT scans of a 3,500 year-old mummy with
calcified coronary arteries. Trying not to be outdone, I
joked that on close observation the images also revealed a
stent in the LAD! Actually, imaging and interventions are
virtually inseparable, as are our respective journals.Despite our specialty reaching its middle age, the
vitality evident in the work reported at ACC.11 and i2
Summit 2011, as well as the skillful organization of the
interventional aspects of the program by Dr. David
Moliterno (another Associate Editor of JACC:
Cardiovascular Interventions) and his team bode well for
the future of our specialty. As Dr. David Holmes said so
passionately to the new fellows inducted at the
Convocation, “The future is all about you.” We all must
support this new generation of physicians and scientists
who will develop the new, yet-to-be-imagined therapies
that will justify our specialty by improving the lives of our
patients.
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